Rapidly climbing sales of the new obesity drug Zepbound and its counterpart for diabetes, Mounjaro, pushed Eli Lilly to a better-than-expected first-quarter profit.
The drugmaker also hiked its sales and earnings forecast for 2024 beyond Wall Street’s expectations even as it hustles to boost manufacturing and catch up to surging demand for the drugs.
Lilly said it was still dealing with supply issues that also hampered the company in the fourth quarter. Company officials expect that to persist through this year, but they emphasized Tuesday that help was on the way.
They expect significant manufacturing increases to occur, starting in the back half of the year.
CEO David Ricks told analysts Tuesday that Lilly was undergoing “the most ambitious expansion plan in our company’s history.”
Indianapolis-based Eli Lilly and Co. recorded $517 million in sales from Zepbound, which received approval from U.S. regulators last November. Total Mounjaro sales more than tripled to $1.81 billion from $568 million in last year’s quarter.
Related articles:
Related suggestion:
Angie Harmon sue Instacart, former shopper who shot and killed her dogUN reports improved prospects for the world economy and forecasts 2.7% growth in 2024It Ends With Us first official trailer released! Blake Lively shares steamy scene with coThree soccer players arrested over alleged matchNational political themes will lead off the campaign for Pennsylvania's next attorney generalHow Anya TaylorTheft of more than 400 vehicles in Michigan leads to the arrest of 6 menPreakness is up next for Brian Hernandez after winning the Derby with a perfect trip on Mystik DanSquad sizes for Copa America teams expanded from 23 players to 26Netflix announces hit show will be axed after just two seasons
2.0994s , 6500.6796875 kb
Copyright © 2024 Powered by Lilly rides Mounjaro, Zepbound to better ,Culture Circuit news portal